Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

Helix Biopharma Corp. Announces Board Composition Changes

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results

Helix BioPharma Responds to Market Activity

Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025

Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025

Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting

Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025

Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones

Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group

Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.

Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan

Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025

Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain

HBP Stock: Why It Substantially Increased Today

HBP Stock Increases Over 19% Pre-Market: Why It Happened

HBP Stock: From $4.19 To $5.04 (20.29% Increase) After Hours Explanation